Meiji Holdings Co Ltd
OTC:MEJHY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (6.6), the stock would be worth $10.45 (10% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 7.3 | $11.55 |
0%
|
| 3-Year Average | 6.6 | $10.45 |
-10%
|
| 5-Year Average | 6.3 | $9.98 |
-14%
|
| Industry Average | 8.2 | $12.92 |
+12%
|
| Country Average | 8.7 | $13.72 |
+19%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
$1.1T
|
/ |
Jan 2026
¥142.9B
|
= |
|
|
$1.1T
|
/ |
Mar 2026
¥147.9B
|
= |
|
|
$1.1T
|
/ |
Mar 2027
¥157.9B
|
= |
|
|
$1.1T
|
/ |
Mar 2028
¥167.8B
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| JP |
|
Meiji Holdings Co Ltd
OTC:MEJHY
|
1T USD | 7.3 | 22 | |
| JP |
G
|
Goyo Foods Industry Co Ltd
TSE:2230
|
53.2T JPY | 186 542.5 | 540 752.8 | |
| CH |
|
Nestle SA
SIX:NESN
|
205.8B CHF | 14.1 | 23.2 | |
| US |
|
Mondelez International Inc
NASDAQ:MDLZ
|
73.8B USD | 18.3 | 30.1 | |
| FR |
|
Danone SA
PAR:BN
|
43.3B EUR | 9.8 | 23.8 | |
| ZA |
T
|
Tiger Brands Ltd
JSE:TBS
|
48.7B ZAR | 9.4 | 12.8 | |
| US |
|
Hershey Co
NYSE:HSY
|
38.8B USD | 21.3 | 44 | |
| CN |
|
Muyuan Foods Co Ltd
SZSE:002714
|
237.6B CNY | 22 | 24.3 | |
| CN |
|
Foshan Haitian Flavouring and Food Co Ltd
SSE:603288
|
231.2B CNY | 24.7 | 32.8 | |
| ZA |
A
|
Avi Ltd
JSE:AVI
|
32.7B ZAR | 8.6 | 12.7 | |
| CH |
|
Chocoladefabriken Lindt & Spruengli AG
SIX:LISN
|
23.8B CHF | 19.2 | 32.4 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 6.7 |
| Median | 8.7 |
| 70th Percentile | 12.2 |
| Max | 214 699 781.2 |
Other Multiples
Meiji Holdings Co Ltd
Glance View
Meiji Holdings Co., Ltd. has long been a staple in the world of Japanese consumer goods, specifically in the food and pharmaceutical sectors. Established in 2009 as a result of merging Meiji Seika Kaisha, Ltd. and Meiji Dairies Corporation, the company stands as a testament to the power of strategic consolidation, leveraging over a century of expertise from its predecessors. The company's robust product portfolio spans a diverse array of offerings, including dairy products like yogurts and milk, confectioneries like chocolate and candy, as well as nutrition bars and supplements. This triumvirate of product lines allows Meiji Holdings to position itself in both the everyday consumer market and in specialized health-centric industries, exploiting economies of scale and extensive distribution networks that reach far beyond the Japanese archipelago. In the pharmaceutical arena, Meiji Holdings operates under its subsidiary, Meiji Seika Pharma, focusing predominantly on antibacterial drugs, central nervous system treatments, and veterinary products. By integrating research and development with a comprehensive marketing strategy, the company capitalizes on global health trends and regional disease challenges, expanding in markets that emphasize health and dietary improvements. Financially, Meiji Holdings generates revenue by producing goods that tap into both traditional consumer desires and modern nutritional trends. It makes money by introducing high-margin pharmaceutical innovations alongside its well-established consumer brands, thus benefiting from both everyday sales and solutions aimed at pressing global health needs. Together, these strategic components make Meiji Holdings an agile player in a competitive global market, combining heritage with innovation.